SCHEMBL1893025

SCHEMBL1893025

CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3CCc3ccccc3)C2=O)C(=O)c2cc(O)c(O)c(CCc3ccccc3)c2C1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2 P10415 3/20 0.50
MCL1 Q07820 3/20 0.50
BCL2L1 Q07817 2/20 0.50
BCL2A1 Q16548 2/20 0.50
SLC37A4 O43826 2/20 0.38
PGAM1 P18669 1/20 0.38
DAO P14920 2/20 0.38
JUN P05412 1/20 0.37
CASR P41180 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.35
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 2/20 0.35
HPGD P15428 2/20 0.35
MEN1 O00255 1/20 0.35
TTR P02766 1/20 0.35
CYP1A1 P04798 1/20 0.35
CYP3A4 P08684 1/20 0.35
MAPT P10636 1/20 0.35
HSPD1 P10809 1/20 0.35
ALOX15 P16050 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1889138 0.94 PGAM1 (0.45) BCL2MCL1BCL2L1BCL2A1SLC37A4
SCHEMBL1894774 0.90 DAO (0.42) BCL2MCL1BCL2L1BCL2A1SLC37A4
SCHEMBL1892299 0.88 SLC37A4 (0.43) BCL2MCL1BCL2L1BCL2A1SLC37A4
SCHEMBL1891842 0.83 BCL2 (0.37) BCL2MCL1BCL2L1BCL2A1SLC37A4
SCHEMBL1889846 0.81 GPR84 (0.43) BCL2MCL1BCL2L1BCL2A1DAO
SCHEMBL1889013 0.81 PTGS1 (0.40) BCL2MCL1BCL2L1SLC37A4PGAM1
SCHEMBL1885850 0.81 ESR1 (0.40) BCL2MCL1SLC37A4KDM4EMAPT
SCHEMBL19424216 0.79 BCL2 (0.40) BCL2MCL1BCL2L1BCL2A1SLC37A4
SCHEMBL24089057 0.77 SLC37A4 (0.38) BCL2MCL1BCL2L1BCL2A1SLC37A4
SCHEMBL1893084 0.77 BCL2L1 (0.54) BCL2MCL1BCL2L1BCL2A1SLC37A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8937193-B2 Apogossypolone derivatives as anticancer agents SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2015-01-20 US disclosed
US-20110112112-A1 APOGOSSYPOLONE DERIVATIVES AS ANTICANCER AGENTS SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2011-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112112-A1 APOGOSSYPOLONE DERIVATIVES AS ANTICANCER AGENTS CYP17A1, HSD17B7, CYP27A1 BCL2 142/4885MCL1 34/4885BCL2L1 195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.